Article
Presented by Dean G. Assimos, MD, Wake Forest University School of Medicine, Winston-Salem, NC.
Pivotal data for lumasiran in PH1 published in NEJM
Nedosiran explored in primary hyperoxaluria type 3
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA approves androgen inhibitor for metastatic PCa
Blood test could guide treatment for kidney cancer
BCG for bladder cancer in short supply
Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC
Long-term data support radium-223 safety in mCRPC
Survey: New NMIBC treatments face slow uptake
RCT compares platinum/5-FU, platinum/paclitaxel in high-risk penile cancer